Gilead Sciences (NASDAQ:GILD) Insider Sells $371,760.00 in Stock

Gilead Sciences, Inc. (NASDAQ:GILD) insider Johanna Mercier sold 3,000 shares of the stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $123.92, for a total transaction of $371,760.00. Following the sale, the insider directly owned 124,234 shares in the company, valued at approximately $15,395,077.28. The trade was a 2.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Johanna Mercier also recently made the following trade(s):

• On Friday, May 15th, Johanna Mercier sold 28,000 shares of Gilead Sciences stock. The shares were sold at an average price of $131.29, for a total value of $3,676,120.00.
• On Wednesday, April 15th, Johanna Mercier sold 3,000 shares of Gilead Sciences stock. The shares were sold at an average price of $140.96, for a total value of $422,880.00.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $123.76 on Friday. The stock has a market capitalization of $153.66 billion, a price-to-earnings ratio of 16.86 and a beta of 0.31. The stock has a 50-day moving average of $132.01 and a 200 day moving average of $134.29. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. Gilead Sciences, Inc. has a twelve month low of $104.46 and a twelve month high of $157.29.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, beating the consensus estimate of $1.91 by $0.12. The company had revenue of $6.96 billion for the quarter, compared to analyst estimates of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.Gilead Sciences’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same period last year, the company earned $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Sell-side analysts anticipate that Gilead Sciences, Inc. will post -0.8 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be paid a $0.82 dividend. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.7%. Gilead Sciences’s dividend payout ratio (DPR) is currently 44.69%.

Institutional Investors Weigh In On Gilead Sciences

Large investors have recently modified their holdings of the business. Aviva PLC increased its holdings in shares of Gilead Sciences by 5.4% in the fourth quarter. Aviva PLC now owns 1,156,738 shares of the biopharmaceutical company’s stock valued at $141,978,000 after purchasing an additional 59,782 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management boosted its stake in Gilead Sciences by 52.1% during the third quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 78,494 shares of the biopharmaceutical company’s stock worth $8,713,000 after buying an additional 26,882 shares during the last quarter. NewEdge Wealth LLC grew its holdings in Gilead Sciences by 2.9% in the 3rd quarter. NewEdge Wealth LLC now owns 619,690 shares of the biopharmaceutical company’s stock valued at $75,962,000 after buying an additional 17,284 shares in the last quarter. Nordea Investment Management AB grew its holdings in Gilead Sciences by 16.5% in the 4th quarter. Nordea Investment Management AB now owns 5,138,699 shares of the biopharmaceutical company’s stock valued at $630,056,000 after buying an additional 726,101 shares in the last quarter. Finally, Life Cycle Investment Partners Ltd acquired a new stake in shares of Gilead Sciences in the 4th quarter worth $1,418,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

GILD has been the subject of a number of research analyst reports. Argus upped their price objective on shares of Gilead Sciences from $135.00 to $165.00 and gave the stock a “buy” rating in a research report on Thursday, February 19th. Leerink Partners cut their target price on shares of Gilead Sciences from $148.00 to $146.00 in a research note on Friday, May 8th. Truist Financial restated a “buy” rating and set a $157.00 price target (up from $155.00) on shares of Gilead Sciences in a research report on Friday, May 8th. Wall Street Zen lowered shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, Rothschild & Co Redburn lowered their price objective on Gilead Sciences from $170.00 to $167.00 in a report on Monday, May 11th. Twenty-five research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $158.41.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.